Arkolith/Insider Trading/RXRX/Form 4

Gibson Christopher

DirectorRECURSION PHARMACEUTICALS, INC. (RXRX) · full profile →Form 4 · filed Apr 8, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$124K
Net Open-Market Flow
-$124K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 7, 2026Conversion(C)40K—$0947K
Apr 7, 2026Sell(S)40K$3.10$124K907K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 7, 2026Conversion(C)40K—$04.4M

Transaction Codes

C
Conversion of a derivative
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001856369-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML